Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Recruiting
This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration. Participants will be enrolled in one of 2 parts: * In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants * In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from... Read More
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
07/02/2025
Locations: Site # 8400017, Eugene, Oregon
Conditions: Neovascular Age-related Macular Degeneration
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
Recruiting
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD). STELLA-FTD is a multicomponent video-conference based intervention designed to facilitate effective use of community and peer resources to foster effective management of behavioral and psychological symptoms of dementia. The study... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/02/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Frontotemporal Dementia, Caregiver Burden, Primary Progressive Aphasia(PPA), Corticobasal Syndrome
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Recruiting
This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Clackamas Radiation Oncology Center, Clackamas, Oregon
Conditions: Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Lung Non-Small Cell Carcinoma
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Portland, Oregon
Conditions: Metastatic Colorectal Cancer
Descemet Endothelial Thickness Comparison Trial I
Recruiting
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose of this study is to determine differences in visual outcomes between two types of corneal transplant surgeries, ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK), and to determine the effect of rho-kinase inhibitors on e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Fuchs
Descemet Endothelial Thickness Comparison Trial II
Recruiting
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: Legacy Emanuel Children's Hospital, Portland, Oregon
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/30/2025
Locations: Oregon Health, Portland, Oregon
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Recruiting
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Casey Eye Institute OHSU, Portland, Oregon
Conditions: Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Enhancing Prospective Thinking in Early Recovery (PARK)
Recruiting
The goal of this clinical trial is to demonstrate the commercial potential for a novel virtual reality (VR) intervention in preparation for Phase II development. This clinical trial will test the VR intervention for efficacy in reducing opioid use, increasing abstinence, and other self-reported and behavioral focus on future outcomes in individuals in early recovery from opioid use disorder. * Will the VR group, compared to the control group, have a lower number of opioid use days? * Will the V... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/27/2025
Locations: Serenity Lane Alcohol & Drug Treatment, Coburg, Oregon
Conditions: Opioid Use, Opioid Use Disorder, Substance Use Disorders
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Legacy Health, Portland, Oregon
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Recruiting
The X-TOLE2 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Providence Brain & Spine Institute, Portland, Oregon
Conditions: Focal Onset Seizures